However, the following treatment options are available: The antiviral drug tecovirimat: Approved by the US Food and Drug Administration [FDA] for the treatment of smallpox—available in oral and IV formulations from the CDC via an Expanded Access Investigational New Drug (IND) protocol for the primary or early empiric treatment of mpox in all ages; approved for smallpox and mpox in the European Union The antiviral drugs cidofovir (commercially available) or brincidofovir (CMX001, available via single-patient emergency use IND) Vaccinia immune globulin (IV), available from the CDC via an Expanded Access IND protocol Trifluridine ophthalmic solution for ocular lesions All of these drugs have activity against mpox in vitro and in experimental models, but there are no data available yet that demonstrate clinical effectiveness.